May 19, 2021 / 05:55PM GMT
Brian Abrahams - RBC Capital Markets - Analyst
Hi, good afternoon, everyone. I am Brian Abrahams, Senior Biotech Analyst here at RBC Capital Markets. Our next presenting company is IGM Biosciences, represented by their CEO, Fred Schwarzer. Fred, thanks so much for joining us.
Fred Schwarzer - IGM Biosciences, Inc. - CEO
Thanks very much, Brian.
Questions and Answers:
Brian Abrahams - RBC Capital Markets - AnalystSo, maybe, just to kick things off for those who are newer to the story, can you maybe start off by giving us an overview on your overall platform and why you guys have decided to use IgM antibodies rather than the more traditional IgGs? And we are also curious to learn how you have managed to overcome some of the challenges with IgM technology that have held the field back in the past?
Fred Schwarzer - IGM Biosciences, Inc. - CEO
Sure. Well we've decided to use IgMs (technical difficulty). Sorry for the technical difficulties. We managed to overcome a lot of